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We have developed a monoclonal antibody (MAb), C7, that reacts with the Als3p and enolase present in the
Candida albicans cell wall and exerts three anti-Candida activities: candidacidal activity and inhibition of both
adhesion and filamentation. To investigate the mode of action of MAb C7 on fungal viability, we examined
changes in the genome-wide gene expression profile of C. albicans grown in the presence of a subinhibitory
concentration of MAb C7 (12.5 g/ml) by using microarrays. A total of 49 genes were found to be differentially
expressed upon treatment with MAb C7. Of these, 28 were found to be upregulated and 21 were found to be
downregulated. The categories of upregulated genes with the largest number of variations were those involved
in iron uptake or related to iron homeostasis (42.86%), while the energy-related group accounted for 38.10%
of the downregulated genes (8/21). Results were validated by real-time PCR. Since these effects resembled those
found under iron-limited conditions, the activity of MAb C7 on C. albicans mutants with deletions in key genes
implicated in the three iron acquisition systems described in this yeast was also assessed. Only mutants lacking
the TPK1 gene and, to a lesser extent, the TPK2 gene were less sensitive to the candidacidal effect of MAb C7.
FeCl3 or hemin at concentrations of >7.8 M reversed the candidacidal effect of MAb C7 on C. albicans in a
concentration-dependent manner. The results presented in this study provide evidence that the candidacidal
effect of MAb C7 is related to the blockage of the reductive iron uptake pathway of C. albicans.
Members of the genus Candida and, in particular, Candida
albicans are opportunistic pathogens frequently isolated from
the mucosal surfaces of immunocompetent individuals. In
patients with predisposing conditions, including immunode-
ficiencies, pregnancy, or diabetes mellitus, or those receiving
broad-spectrum antibiotics, C. albicans may cause mucosal
and systemic infections, which are frequently treated with
azole, polyene, or echinocandin antifungal agents. Although
these antifungal agents are active against most Candida iso-
lates, emergence of resistance has become a serious concern
(23). In recent years, considerable interest has been attracted
by the antifungal activity of some antibodies (15, 22, 24, 26),
but further work is needed in light of the fact that the develop-
ment of the most promising among them (30) (Mycograb; No-
vartis) has recently been discontinued (http://www.novartis.com
/newsroom/media-releases/en/2010/1449020.shtml).
We developed a monoclonal antibody (MAb), designated
C7, against a stress mannoprotein of 200 kDa from the cell
wall of C. albicans. This antibody reacted with a peptide
epitope present in Als3 as well as in a number of antigens from
the blastoconidium and germ tube cell walls, including enolase
(4, 29). MAb C7 also reacts with antigens present in Candida
krusei, Candida tropicalis, Candida glabrata, Candida dublini-
ensis, and Candida lusitaniae, as well as in Cryptococcus neo-
formans, Scedosporium prolificans, and Aspergillus fumigatus.
We focused our attention on this antibody since it exhibited a
fungicidal effect on C. albicans and on a group of clinically
relevant and emergent fungi, including C. neoformans, A. fu-
migatus, the amphotericin B-resistant organism C. lusitaniae,
and the multiresistant organism S. prolificans (26). In addition
to its fungicidal effect, MAb C7 exerts two other important
biological activities: inhibition of adherence of C. albicans to
HEp-2 cells and inhibition of germination (26). MAb C7 has
been proved to be protective in a murine model of systemic
candidiasis (37). The biological activities of MAb C7 have been
reproduced by peptides with the amino acid sequence of some
of its complementarity sequence-determining regions (32).
The completion of the C. albicans genome sequence and the
availability of a database dedicated to the C. albicans genome
have greatly facilitated the use of the functional genomics
approach to study the interaction of antifungal agents with this
pathogenic fungus (6, 14). In order to investigate the mode
of action of MAb C7, we used genome-wide expression
profiling to identify genes differentially expressed in re-
sponse to MAb C7.
MATERIALS AND METHODS
Fungal strains and culture conditions. All strains used in the present study are
listed in Table 1. Strains were cultured in YPD medium (2% peptone [Labora-
torios Conda S.A., Madrid, Spain], 1% yeast extract [Laboratorios Conda], 2%
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glucose [Panreac Química S.A.U., Barcelona, Spain]) at 30°C, with 2% agar
included for solid media.
C. albicans treatment for microarray experiments. C. albicans SC5314 was
grown overnight in modified Lee’s medium (42) at 22°C and 120 rpm, and then
it was diluted with fresh medium to reach an optical density at 600 nm (OD600)
of approximately 0.1. The diluted culture was split into two aliquots, and MAb C7
was added to one of them at a final concentration of 12.5 g/ml, a subinhibitory
concentration that reduced the fungal growth without being fungicidal. Incuba-
tion time was extended up to 18 h at 37°C to obtain enough sample to be
processed, and the morphology developed by Candida cells in both cultures was
mycelial. An aliquot was saved to calculate the extent of growth.
RNA preparation and microarray hybridization. Two independent sets of
RNA isolated from control and MAb C7-treated cells (12.5 g/ml; biological
replicates), respectively, were used in these studies to prepare two independent
cDNA probe sets. The isolation of total RNA, preparation of Cy3- and Cy5-
cDNA, and pairwise hybridization to DNA microarrays were performed accord-
ing to Galar Fungail standard operating procedures (www.pasteur.fr/recherche
/unites/Galar_Fungail/) with minor modifications. cDNAs were purified by a
QIAquick PCR purification kit (Qiagen, Valencia, CA) and eluted from columns
by rinsing twice with 50 l of water (42°C). The eluate was concentrated to a
volume of 10 l using Microcon-YM30 columns (Millipore, Billerica, MA). Five
microliters each of Cy3- and Cy5-labeled cDNA and herring sperm DNA (10
mg/ml) were mixed, denatured at 95°C for 2 min, and then quickly chilled on ice.
Forty microliters of hybridization mixture was added, and the solution was placed
onto DNA microarray slides, which were covered with a rimmed cover glass
(Erie Scientific, Portsmouth, NH). Slides were placed in a hybridization chamber
(Corning, Palo Alto, CA) and hybridized for 24 h at 42°C by immersion in a water
bath. The C. albicans microarrays used in this study were manufactured by
Eurogentec SA (Ivoz-Ramet, Belgium) in collaboration with the European Galar
Fungail Consortium. The microarrays were scanned using a GenePix4000B mi-
croarray scanner (Axon Instruments, Inc., Union City, CA).
Microarray data analysis. GenePix Pro (version 4.0.1.12) software (Axon
Instruments, Inc.) was used for image analysis and data visualization. Each
microarray was inspected to identify low-quality spots, which were not included
in the analysis. Preliminary normalization, logarithmic transformation, and de-
termination of correlation coefficients were performed with the Excel 2000 pro-
gram (Microsoft, Redmond, WA). Data from at least two independent experi-
ments using independent cultures and including one dye-swap experiment were
evaluated with GeneSpring (version 5.0) software (Silicon Genetics, Redwood
City, CA) and normalized in a per-chip (to the 50th percentile) and per-gene (to
the median) way. Median F635, F532, B635, and B532 of each spot (median
values for the foreground [F] and background [B] of the red [635] channel and
green [532] channel corresponding to Cy5 and Cy3 labeling, respectively) were
loaded into GeneSpring for calculation of signal and background intensities.
Signals were log transformed and normalized per chip by an intensity-dependent
(Lowess) method applied to the print-tip region (46). Significance analysis was
applied to detect genes with differential expression in MAb C7-treated versus
nontreated cultures. Normalized gene expression values for all the treated sam-
ples were averaged and compared to the average value for all the nontreated
samples. A combination of nonparametric tests (P  0.02) was used for ranking
the genes, and Benjamini’s correction for the false discovery rate (FDR) was
applied (43). For gene listings, we defined genes to be significantly regulated if
they were up- or downregulated by at least a factor of 1.5. DNA sequences were
annotated on the basis of results of BLASTn searches using the CandidaDB
database (http://www.pasteur.fr/Galar_Fungail/CandidaDB/).
Assessment of functional categories of genes. The sets of selected genes that
were significantly up- or downregulated by at least a factor of 1.5 were analyzed
with the gene ontology (GO) term enrichment tool (AmiGO’s Term Enrich-
ment; http://amigo.geneontology.org/cgi-bin/amigo/term_enrichment) with the
aim of discovering what they may have in common by examining annotations and
finding significant shared GO terms. The inputs were filtered through the Can-
dida Genome Database (CGD; for Candida albicans) in order to remove any
possible ambiguity. The predicted open reading frame (ORF) orf19.3522, re-
garded as dubious at CGD, was excluded from the set of upregulated sequences
during this filtering.
Quantitative real-time RT-PCR. Samples of RNA isolated from untreated and
MAb C7-treated cells, like those used in the microarray experiments, were
processed for quantitative real-time reverse transcription (RT)-PCR follow-up
studies. First-strand cDNAs were synthesized from 2 g of total RNA in a 21-l
reaction volume using a SuperScript first-strand synthesis system for RT-PCR
(Invitrogen, Carlsbad, CA), in accordance with the manufacturer’s instructions.
Quantitative real-time PCR was performed in triplicate using a 7300 sequence
detection system (Applied Biosystems, Foster City, CA). Independent PCRs
were performed using the same cDNA for both the gene of interest and the 18S
rRNA, using SYBR green PCR master mix (Applied Biosystems). Gene-specific
primers for the gene of interest and the 18S rRNA were designed using Primer
Express software (Applied Biosystems), and their sequences are listed in Table
2. The PCR conditions consisted of AmpliTaq Gold activation at 95°C for 10
min, followed by 40 cycles of denaturation at 95°C for 15 s and annealing/
extension at 60°C for 1 min. A dissociation curve was generated at the end of
each PCR cycle using software provided with the 7300 sequence detection system
to verify that a single product was amplified. The change in fluorescence of
SYBR green I dye in every cycle was monitored by the system software, and the
threshold cycle (CT) above the background for each reaction was calculated. The
CT value of 18S rRNA was subtracted from that of the gene of interest to obtain
the differential value (CT). The CT value of an arbitrary calibrator (e.g.,
untreated sample) was subtracted from the CT value of each sample to obtain
a CT value. The gene expression level relative to the calibrator was expressed
as 2CT.
Candidacidal activity. The candidacidal activity of MAb C7 was assessed by a
modification of the method described previously (26). C. albicans cells grown
overnight in an orbital shaker in Sabouraud’s broth at 22°C and 120 rpm were
collected and suspended in sterile phosphate-buffered saline (PBS; pH 7.3). At
this point, 150 viable C. albicans cells suspended in 100 l of PBS were exposed
to MAb C7 at 0.1 mg/ml. Parallel samples were run with an irrelevant mouse
monoclonal IgM (TEPC183; Sigma-Aldrich Química S.A., Madrid, Spain). After
18 h of incubation at 37°C, the fungal cells were collected and spread on Sab-
ouraud dextrose agar plates. The number of CFU was recorded after 48 h of
incubation at 37°C. All values quoted represent mean figures derived from at
least three independent assays performed in triplicate. In order to reproduce the
conditions used in the microarray experiments, the candidacidal activity of MAb
C7 was also assessed in Lee’s medium (42) supplemented with uridine (Sigma)
at 0.1 g/liter and amino acids (ornithine, 0.0714 g/liter; phenylalanine, 0.5 g/liter;
threonine, 0.5 g/liter; proline, 0.5 g/liter; histidine, 1 g/liter; Sigma). All values
TABLE 1. C. albicans strains used in this study
Strain Genotype Parental strain Reference
NCPF3153a Wild type 10
SC5314 Wild type 9
CAI-4 ura3::imm434/ura3::imm434 9
AS1 tpk2::hisG/tpk2::hisG CAI-4 39
BCa18-2 rbt5::hisG/rbt5::hisG-URA3-hisG ura3/ura3 CAI-4 3
C4-SHB1.1 sit1::hisG-URA3-hisG/sit1::hisG CAI-4 11
IIHH6-4a tpk1::hisG/tpk1::hisG CAI-4 2
KC85 ura3/ura3 rbt51::hisG/rbt51::hisG-URA3-hisG CAI-4 44
1843 iro1-ura3:: imm434/iro1-ura3:: imm434 als3la/als3sa-URA3 CAI-4 49
BWP17 ura3:: imm434/ura3:: imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG 45
CT87.4 Caftr1::ARG4/Caftr1::URA3 his1/his1 BWP17 16
YLO166 ura3:: imm434/ura3:: imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG
TR-CaENO1/tetRHIS1-Caeno1::ARG4
BWP17 47
a NCPF, National Collection of Pathogenic Fungi (Bristol, United Kingdom).
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quoted represent mean figures derived from at least three independent assays
performed in triplicate.
C. albicans NCPF3153 cells incubated with MAb C7 were checked microscop-
ically for the presence or the absence of cell agglutination. MAbs 26G7 and 14-8
were used as controls (8).
Inhibition of metabolic activity. The inhibition of metabolic activity by MAb
C7 was studied by the 3-(4,5-dimethytiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) reduction assay (27). MTT is a tetrazolium salt which is reduced to
a colored formazan product by reducing enzymes present only in metabolically
active living cells. Briefly, 107 cells of C. albicans in 100 l of PBS were incubated
with 0.1 mg/ml of MAb C7 for 18 h at 37°C in an enriched 5% CO2 atmosphere
in 96-well microtiter plates (Greiner Bio-One GmbH, Frickenhausen, Germany).
After centrifugation at 600  g for 8 min, the supernatants were discarded and
100 l of MTT (Sigma) dissolved in RPMI-PS at a concentration of 0.5 mg/ml
was added to each well. The plates were then incubated for 3 h at 37°C in a 5%
CO2 atmosphere, and supernatants were discarded after centrifugation at 600 
g for 8 min. One hundred microliters of dimethyl sulfoxide (DMSO; Sigma) was
added to each well, and the formation of the formazan product was measured at
490 nm in a microplate reader (ELx808; Biotek, Winooski, VT). Each assay was
performed in triplicate.
A LIVE/DEAD yeast viability kit (Molecular Probes, Eugene, OR) was also
used to study the inhibition of metabolic activity by MAb C7 (0.1 mg/ml). The
vital stain FUN-1, which is processed by metabolically active yeast cells and
which results in a shift from green to red fluorescence within vacuolar structures,
was used as described elsewhere (25). FUN-1-stained cells were observed under
an epifluorescence microscope (Eclipse 80i; Nikon, Tokyo, Japan) with an exci-
tation filter wavelength of 482/535 nm and an emission filter of 536/540 nm for
green and red colors, respectively. The proportions of dead and alive cells were
calculated by direct counting.
Influence of different iron sources on the candidacidal activity of MAb C7. C.
albicans strains were grown in an orbital shaker at 120 rpm and 30°C for 18 h in
YPD broth supplemented with the iron chelator bathophenanthroline disulfonic
acid disodium salt (0.5 mM; Sigma). Subsequently, the cultures were diluted 1:4
in the same medium and reincubated for an additional period of 18 h for iron
starvation. Cells were washed twice in PBS and then used in the assay at a final
concentration of 1.5  104 cells/ml of Lee’s medium (42) supplemented with
uridine (0.1 g/liter; Sigma) and amino acids (ornithine, 0.0714 g/liter; phenylal-
anine, 0.5 g/liter; threonine, 0.5 g/liter; proline, 0.5 g/liter; histidine, 1 g/liter;
Sigma). Ferritin (type I, from horse spleen; Sigma) was prepared as described
elsewhere (1) and tested at a final concentration of 20 g/ml. MAb C7 and an
irrelevant IgM MAb (TEPC183; Sigma) were tested at a final concentration of
0.1 mg/ml. After incubation at 30°C in an orbital shaker (120 rpm) for 18 h, the
yeasts were plated onto YPD agar and the numbers of CFU were counted after
incubation at 30°C for 48 h. Results were expressed as percent growth inhibition
compared to the growth of the respective control treated with an irrelevant IgM.
In a series of experiments, C. albicans cells were grown overnight in Sabouraud
broth at 22°C in an orbital shaker at 120 rpm and then collected, washed twice
in PBS, and then resuspended in sterile PBS, pH 7.3. At this point, 150 viable C.
albicans cells suspended in PBS were exposed to MAb C7 at a concentration 0.1
mg/ml in combination with different concentrations of iron(III) chloride hexa-
hydrate (Merck, Darmstadt, Germany) or hemin (Sigma). Parallel samples were
run with an irrelevant mouse IgM MAb (TEPC183; Sigma).
Influence of ferrozine on C. albicans growth. For assay of the influence of
ferrozine on C. albicans growth, C. albicans NCPF 3153 was grown in YPD broth
in an orbital shaker (120 rpm) at 30°C for 18 h. Then, cells were washed twice in
PBS and used in the assay at a final concentration of 1.5  104 cells/ml in PBS
or in YPD broth supplemented with 3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-
4,4-disulfonic acid sodium salt (ferrozine; Sigma) at a final concentration of 10
mM when the assay was performed in PBS or 100 mM when it was performed in
YPD broth. After incubation at 30°C for 14 h in an orbital shaker (120 rpm), cells
were plated onto Sabouraud agar and incubated at 37°C for 48 h, and the number
of CFU was counted. No ferrozine was added to the positive control. Results
were expressed as percent growth inhibition compared to the growth of a control
treated with an irrelevant IgM.
Statistical analysis. Statistical significance was calculated with the Students t
test function in Microsoft Excel. P values of 	0.05 were considered statistically
significant. All values quoted represent mean figures derived from at least three
independent assays performed in triplicate.
Microarray data accession number. Microarray raw data have been deposited
in the NCBI Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm
.nih.gov/geo/) and are accessible through GEO series accession number
GSE25969.
RESULTS
Candidacidal and metabolic inhibitory activity of MAb C7.
C. albicans NCPF 3153 does not multiply in PBS but cells
remain viable, and the treatment with MAb C7 (0.1 mg/ml)
produced a 43.4% 
 1.47% reduction in the number of CFU
compared to the number for the control treated with a com-
mercial IgM. Beyond that, in Lee’s medium, where C. albicans
can grow, treatment with MAb C7 produced a 98.97% 

0.51% decrease in the CFU count (Table 3). In contrast to
control MAbs 26G7 and 14-8, which showed a strong agglu-
tinating effect, MAb C7 did not agglutinate the cells of C.
albicans (data not shown), so the reduction in the number of
CFU could not be due to yeast cell agglutination mediated
by MAb C7.
This candidacidal effect of MAb C7 was also characterized
by measuring the metabolic activity of C. albicans through the
MTT assay. As expected, incubation with MAb C7 (0.1 mg/ml)
in PBS reduced the metabolic activity of C. albicans to
35.20% 
 3.77% compared to that of the control incubated
with an irrelevant MAb (P  0.03). To further confirm this
inhibitory effect, we used a vital staining technique with the
FUN-1 probe and registered that metabolically active cells
dropped to 31.4% 
 2.38 after incubation with MAb C7 (P 
0.016; Fig. 1).
Gene expression response to MAb C7 exposure. C. albicans
SC5314 was grown in modified Lee’s medium (42) and diluted
TABLE 2. Primer sequences for mRNA analysis by real
time RT-PCR
Gene Primer paira Ampliconsize (bp)
18S F, 5-CACGACGGAGTTTCACAAGA-3 135b
R, 5-CGATGGAAGTTTGAGGCAAT-3
CTR1 F, 5-TCATCTTCTACTTCCTCATCATCGG-3 52b
R, 5-CGTGGTCCATACCTTCCATAGC-3
FET34 F, 5-ATGAGGAGGAGGAAGAACAAAGC-3 58b
R, 5-GGGCTAGAAGAGGAACCAGTTG-3
FRE7 F, 5-CCCTAAGCCCAAATACTGGAAAT-3 51b
R, 5-TGAATAAACACATGACCGCCA-3
FTR1 F, 5-GAAAGAGGTGGCTGGACTATTCA-3 57b
R, 5-TTTTACCATTCATTACTTGTTTGCG-3
RBT5 F, 5-GTTCTGTTGAATCTTTGGCCAC-3 100
R, 5-AGCCTTAGCCAAAGCGTCA-3
SIT1 F, 5-CTGCCAGTCAACCCGTCTATG-3 55b
R, 5-AACTCCAAACGACCAAGGACAT-3
NDH51 F, 5-TCACACTATTTGCGCCTTGG-3 113
R, 5-CCAGCGTGTTTTTGTTGGAA-3
QCR8 F, 5-GGTGCACCACATCCACATACTT-3 113
R, 5-CCCCTTTAATGGTTTAGCAGCA-3
ZRT1 F, 5-AACCATGACGCTGTGACTTGTG-3 110
R, 5-TGGACCAAAAGACCCGATACC-3
a F, forward; R, reverse.
b References 19 and 20.
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with fresh medium to reach an OD600 of 0.1. The diluted
culture was split into two aliquots, and MAb C7 was added to
one of them. As the MAb concentration of 12.5 g/ml was
subinhibitory, we had to extend the incubation up to 18 h at
37°C in order to obtain enough sample to be processed. Can-
dida morphology of both cultures was mycelial. Two indepen-
dent sets of RNA isolated from control and MAb C7-treated
cells, respectively, were used to prepare two independent
cDNA probe sets. A total of 50 genes were found to be differ-
entially expressed upon treatment with MAb C7. Of these, 29
were found to be upregulated and 21 were found to be down-
regulated (Table 4). orf 19.3522 was excluded by the AmiGO
algorithm, due to its attributed dubious nature in the CGD;
thus, only 28 genes were considered upregulated for the fol-
lowing calculations. The categories of upregulated genes with
the largest extent of variation were those involved in iron
acquisition and homeostasis (12/28  42.86%). It is notewor-
thy that other upregulated genes are those encoding glycosyl-
phosphatidylinositol (GPI) anchor proteins (6/28  22.43%)
and genes involved in cell stress responses (2/28  7.14%).
However, among downregulated genes, the energy-related
group accounted for 38.10% of the inputs (8/21).
Validation of microarray data by real-time RT-PCR. Real-
time RT-PCR was performed for nine genes of interest to
validate data from microarray analysis. Genes were selected on
the basis of their role in iron uptake and in energetic metab-
olism. In general, we found a good correlation between real-
time RT-PCR results and microarray data. For instance, RBT5,
the gene showing the highest overexpression by the microarray
analysis, was also highly upregulated by real time RT-PCR
analysis (Fig. 2).
Candidacidal activity of MAb C7 on C. albicans mutants
lacking key genes of the iron acquisition systems. Since the
expression data resembled those of an iron depletion condition
and the effect was very similar to that observed with the anti-
fungal agent ciclopirox olamine against C. albicans (28), we
examined the effect of MAb C7 on several mutants lacking key
genes from iron uptake pathways. Most of the C. albicans
mutants tested behaved similarly to the control reference and
parental strains (Table 3). Only the mutant lacking the TPK1
gene showed a significant reduction in the percentage of
growth inhibition in the presence of MAb C7. The tpk1/tpk1
mutant showed 48.38% 
 8.03% inhibition of growth, and the
tpk2/tpk2 mutant showed 91.88% 
 0.51%. Additionally,
one mutant of C. albicans lacking the ALS3 gene and another
mutant heterozygous for ENO were also susceptible to MAb
C7 (Table 3).
Influence of iron on activity of MAb C7. To further investi-
gate the relationship between the candidacidal effect of MAb
C7 and iron acquisition in C. albicans, we examined the effect
of MAb C7 on fungal cells in the presence of different iron
sources. Iron(III) chloride reduced the inhibitory effect of
MAb C7 on C. albicans NCPF3153 in a concentration-related
manner, and concentrations of 62.5 M neutralized the
growth inhibition caused by the MAb (Fig. 3). Similar results
were observed using C. albicans SC5314 (data not shown). The
candidacidal activity of MAb C7 on C. albicans was also re-
duced by hemin, with its effect being more efficacious with
increasing concentrations (7.8 M; Fig. 3); unfortunately, we
were unable to run experiments with hemin concentrations of
31.2 M due to its reduced solubility.
Contrarily, ferritin (20 g/ml) was not able to revert the
candidacidal effect of MAb C7 on C. albicans NCPF3153 grow-
ing in Lee’s medium (98.97% 
 0.51% inhibition of growth in
the absence of ferritin and 98.68% 
 0.91 with ferritin). Sim-
ilar results were obtained with strain SC5314 (95.92%
 0.14%
inhibition without ferritin and 94.25% 
 1.16% with ferritin).
The growth of C. albicans in the presence of the iron chela-
tor ferrozine (100 mM) was inhibited to an extent similar to
the inhibition produced by MAb C7 (99.86% 
 0.02% and
98.97% 
 0.51% of control growth, respectively).
DISCUSSION
Results presented in this study confirm and extend our pre-
vious observation regarding the candidacidal activity of MAb
C7 (26), which seems to be independent of the growth condi-
tions since it is effective on either growing or resting cells. MAb
C7 is not the only MAb described as being fungicidal. In this
way K10, an antibody that mimics the activity of a Pichia
FIG. 1. Metabolic status of C. albicans NCPF3153 cells after treat-
ment with MAb C7, measured by using the vital staining FUN-1,
compared with that after treatment with an irrelevant IgM. Mean
values 
 standard deviations represent mean figures derived from at
least three independent assays.
TABLE 3. Activity of MAb C7 (0.1 mg/ml) on C. albicans strains in
modified Lee’s medium
Straina % growthinhibitionb 
 SD P value
c
NCPF3153 98.97 
 0.51
SC5314 95.92 
 0.14
CAI-4 97.69 
 0.47
AS-1 (tpk2/tpk2) 91.88 
 0.51 0.020
BCA 18-2 (rbt5/rbt5) 93.40 
 1.25 0.065
C4-SHB1.1 (sit1/sit) 97.90 
 0.65 0.366
II HH6-4a (tpk1/tpk1) 48.38 
 8.03 0.036
KC85 (rbt51/rbt51) 95.29 
 0.49 0.045
1843 (als3/als3) 98.40 
 2.26 0.338
BWP-17 96.55 
 0.32
CT87.4 (ftr1/ftr1) 99.63 
 0.13 0.034
YLO166 (TR-CaENO1/Caeno1) 93.73 
 0.91 0.111
a CAI-4 and BWP-17 are parental strains of those listed indented below;
CAI-4, in turn, is derived from SC5314.
b Percent growth inhibition with respect to the growth of the same strain
treated with a commercial IgM.
c Values of percent growth inhibition for each strain were compared with those
yielded by the respective parental strain (CAI-4 or BWP-17) through the Student
t test function. Statistical significance was set at a P value of 	0.05.
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TABLE 4. Changes in C. albicans gene expression in response to treatment with MAb C7 12.5 g/ml of Lee’s medium
Gene function and name Function Fold change inexpression
Amino acid metabolism
ARO8 orf19.2098 Aromatic transaminase of the Ehrlich fusel oil pathway of aromatic alcohol biosynthesis 1.5
CYS3 orf19.6402 Predicted enzyme of sulfur amino acid biosynthesis 1.5
CSH1 orf19.4477 Aldo-keto reductase family member, similar to aryl alcohol dehydrogenases 0.6
IFD6 orf19.1048 Aldo-keto reductase family member, similar to aryl alcohol dehydrogenases 0.6
SDH12 orf19.2871 Protein with similarity to S. cerevisiae SDH1, which is a flavoprotein subunit of succinate
dehydrogenase; molecular function unknown
0.6
Cell stress
COI1 orf19.5063 Secreted protein; ciclopirox olamine induced; regulated by Ssn6p; induced by nitric
oxide in yhb1 mutant; molecular function unknown
1.8
AOX2 orf19.4773 Alternative oxidase 1.7
HSP12 orf19.3160 Heat shock protein 0.6
SOD5 orf19.2060 Copper- and zinc-containing superoxide dismutase 0.5
Energy
COX13 orf19.1467 Cytochrome c oxidase 0.6
COX5 orf19.4759 Cytochrome c oxidase subunit V 0.6
IDP2 orf19.3733 Putative isocitrate dehydrogenase 0.6
FESUR1 orf19.6794 Protein described as ubiquinone reductase 0.6
IPF690.3F orf19.7591 Protein described as NADH-ubiquinone oxidoreductase 0.6
PCK1 orf19.7514 Phosphoenolpyruvate carboxykinase 0.6
NDH51 orf19.4495 Subunit of NAD dehydrogenase complex I of the mitochondrial electron transport chain 0.5
QCR8 orf19.4490.2 Putative ubiquinol cytochrome c reductase 0.5
Glycosylphosphatidylinositol anchor
cell wall proteins
RBT5 orf19.5636 GPI-anchored cell wall protein involved in hemoglobin utilization; repressed
by TUP1 protein
8.4
RBT51 orf19.5674 PGA10; plasma membrane protein involved in heme iron utilization 6.3
PGA7 orf19.5635 Protein described as a putative precursor of a hyphal surface antigen 4.3
CSA2 orf19.3117 Mycelial surface antigen; unknown function 3.4
PGA18 orf19.301 Putative GPI-anchored protein of unknown function; regulated by Nrg1p and Tup1p 2.7
CSA1 orf19.7114 Surface antigen on elongating hyphae and buds 2.2
BGL22 orf19.7339 Putative glucanase; induced during cell wall regeneration 0.6
Heme biosynthesis and heme-
containing proteins
CYB5 orf19.7049 Cytochrome b5 0.6
CYT1 orf19.3527 Cytochrome c1 0.6
Iron acquisition/uptake
FRP1 orf19.5634 Alias FRE5; predicted ferric reductase 3.1
SIT1 orf19.2179 Transporter of ferrichrome siderophores but not ferrioxamine B 3.0
CTR1 orf19.3646 Copper transport protein 2.5
FET34 orf19.4215 Putative multicopper ferroxidase 2.2
FTR1 orf19.7219 High-affinity iron permease 2.1
FRE7 orf19.6139 Protein similar to ferric reductase Fre10p 2.0
FET3 orf19.4211 Multicopper oxidase; required for growth under low-iron conditions 1.8
SMF12 orf19.2270 Similar to S. cerevisiae Smf1p, which is a manganese transporter 1.6
CCC2 orf19.4328 Copper-transporting P-type ATPase of Golgi; required for wild-type iron assimilation 1.5
FRE30 orf19.6140 Protein with similarity to ferric reductases 1.5
FTH1 orf19.4802 High-affinity iron ion transporter 1.5
FTR2 orf19.7231 High-affinity iron permease 1.5
Iron or iron-sulfur cluster
containing protein
YHB1 orf19.3707 Nitric oxide dioxygenase; acts in nitric oxide scavenging/detoxification 0.6
Transport
GAP6 orf19.6659 Putative general amino acid permease 1.8
DRS25 orf19.2680 S. cerevisiae ortholog DNF3 has phospholipid-translocating ATPase activity, has role in
intracellular protein transport and phospholipid translocation, and localizes to trans-
Golgi network transport vesicle
1.5
GAP4 orf19.4456 Putative amino acid permease; hypha induced 1.5
HGT1 orf19.4527 High-affinity glucose transporter 0.6
ZRT1 orf19.3112 Protein described as zinc transporter; hypha and macrophage induced; alkaline
upregulated by Rim101p; induced upon adherence to polystyrene
0.5
Continued on following page
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anomala killer toxin, shows a potent fungicidal effect on C.
albicans (21, 26).
The gene expression profiling of C. albicans revealed upregu-
lation of genes involved in iron homeostasis to be the main re-
sponse to the treatment with MAb C7. Major changes included
the overexpression of genes CCC2, FET34, FTR1, FTR2, SIT1,
and CTR1. CCC2 encodes a copper-transporting ATPase es-
sential for inorganic iron assimilation pathways. FET34 is a
ferro-oxidase critical for Fe(II) uptake. FTR1 and FTR2 en-
code membrane iron transporters, and SIT1 is a siderophore
transporter involved in iron uptake. Upregulation of all these
genes is consistent with the low-iron-concentration-induced
changes in gene expression observed previously in C. albicans
(16). Furthermore, as copper is essential for Fe(II) uptake in
C. albicans, upregulation of the high-affinity copper trans-
porter CTR1 also supports the hypothesis of a mechanism of
action for the MAb involving iron depletion. In this regard, we
also found that genes encoding cytochromes (CYB5, CYT1)
and flavohemoglobin (YHB1), broadly recognized as being
heme- and iron-containing proteins (5, 48), were downregu-
lated in response to MAb C7.
In addition, we detected many enzyme genes downregulated,
including alcohol dehydrogenases (CSH1, IFD6); phosphoe-
nolpyruvate carboxykinase (PCK1); two members of the tricar-
boxylic acid (TCA) cycle, isocitrate dehydrogenase (IDP2) and
succinate dehydrogenase (SDH12); and superoxide dismutase
(SOD5), which is a component of the cellular defense against
oxidative stress. Lan et al. (18) reported that genes related to
the TCA pathway were more highly expressed under the high-
iron condition; accordingly, our results would point to condi-
tions with limited iron availability. Furthermore, iron depletion
is known to alter the cell surface composition and hydropho-
bicity of C. albicans (31, 41, 42), and we found four genes
encoding GPI-anchored proteins to be upregulated in re-
sponse to MAb C7. In particular was RBT5, a protein from a
family of pathogenesis-related heme-binding proteins (44)
which is highly upregulated under low-iron conditions (16).
One may argue that the observed change in the gene expres-
sion pattern caused by MAb C7 may be a general consequence
of cell growth inhibition. However, treatment of C. albicans
with antifungal drugs such as fluconazole, ketoconazole, flucy-
tosine, and amphotericin B caused expression profiles clearly
different. For example, treatment with amphotericin B resulted
in downregulation of many genes involved in copper (CTR1)
and iron transport (SIT1, FRE30, FTR1, FTR2, FTH1, and
FET33) (20), in contrast to the upregulation in response to
MAb C7.
The transcriptional response of C. albicans to MAb C7 sug-
gests that the fungus is growing under limited iron supply and
supports the theory that MAb C7 antifungal activity may be, at
least partially, caused by iron limitation. This response is sim-
FIG. 2. Quantitative real-time RT-PCR analysis of genes identified
by microarray experiments to be differentially expressed in C. albicans
cells treated with MAb C7. Data are shown as mean values 
 standard
deviations and represent mean figures derived from at least three
independent assays performed in triplicate.
TABLE 4—Continued
Gene function and name Function Fold change inexpression
Unknown function
IPF11316 orf19.511 S. cerevisiae ortholog NRK1 has ribosylnicotinamide kinase activity 1.5
IPF17272.3f orf19.3522a Transcription is downregulated in response to treatment with ciclopirox olamine 1.5
POL93 orf19.6078 With similarity to the Pol region of retrotransposons encoding reverse transcriptase,
protease, and integrase
1.5
IPF3050.2 orf19.7029 Mutation confers hypersensitivity to toxic ergosterol analog 1.5
PRN4 orf19.2461 Protein with similarity to pirins; increased transcription is observed upon benomyl
treatment
0.6
IPF9955 orf19.3499 Regulated by Tsa1p and Tsa1Bp under H2O2 stress conditions; transcriptionally
activated by Mnl1p under weak acid stress
0.6
a This orf is dubious in the current version of CGD for C. albicans and was excluded by the AmiGO Term analysis.
FIG. 3. Influence of iron sources, hemin or FeCl3 (3.9 to 125 M),
on the candidacidal activity of MAb C7 at 0.1 mg/ml of PBS on C.
albicans NCPF3153. Bars represent the percent growth inhibition com-
pared to the growth of the respective control with an irrelevant IgM;
mean values 
 standard deviations from at least three independent
experiments are shown.
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ilar to that registered for C. albicans treated with ciclopirox
olamine, an antifungal drug that acts as an iron chelator, re-
stricting the iron availability to the fungal cell and conse-
quently inhibiting growth (19, 28). In our hands, the presence
of the chelator ferrozine reduced the C. albicans growth extent
in a manner similar to that caused by MAb C7.
C. albicans can acquire iron from siderophores, hemoglobin,
and a variety of ferric iron chelates (16). The membrane trans-
porter Sit1p allows C. albicans to use siderophores as an iron
source (11). The acquisition of iron from hemoglobin is medi-
ated by Rbt5p and Hmx1p (36, 43), whereas multiple genes are
involved in the reductive uptake system that allows Fe(II)
uptake (17). Iron must first be reduced, then captured by a
multicopper oxidase (7), and finally internalized by a ferrous
permease encoded by two highly homologous genes, FTR1 and
FTR2 (33).
One explanation for the mechanism of action of MAb C7 on
C. albicans could be the blockage of one of the iron acquisition
systems. Since the trace amounts of iron in Lee’s medium are
acquired by the reductive pathway, our first hypothesis was that
MAb C7 would be blocking the reductive uptake pathway. To
test this hypothesis, we tried to neutralize the candidacidal
effect of MAb C7 by adding to the medium iron(III) chloride.
Interestingly, high iron concentrations reversed the effect of
MAb C7 on C. albicans, suggesting that MAb C7 was blocking
the reductive pathway. Additional evidence for this hypothesis
comes from the experiments with hemin, which is taken up by
a different uptake system. Addition of hemin to the culture
medium neutralized the candidacidal effect of MAb C7. In
agreement with this hypothesis, supplementation of the culture
medium with ferritin, which is taken up by the reductive uptake
pathway, was not able to sort out the effect of MAb C7.
Taken together, there are several lines of evidence suggest-
ing that the candidacidal effect of MAb C7 is related to the
blockage of iron uptake by the reductive pathway. To obtain
further evidence to support this hypothesis, we tested a num-
ber of C. albicans mutants lacking key genes of each of the
three known iron acquisition systems. The action of MAb C7
on the sit1/sit1, rbt5/rbt5, and ftr1/ftr1 mutants was
similar to that on the C. albicans wild-type strains, suggesting
that the proteins encoded by these genes were not recognized
by MAb C7 or had a location in the cell protected from the
action of the MAb. Since Saccharomyces cerevisiae mutants
lacking TPK2 have permanently activated the siderophore and
the reductive iron uptake systems (35), we assayed the effect of
MAb C7 on C. albicans TPK1 and TPK2 mutants. Both strains
were less sensitive to the action of MAb C7 compared with
their sensitivity to an irrelevant IgM. This behavior could be
expected if C. albicans tpk proteins would negatively regulate
genes involved in iron uptake, as described for S. cerevisiae.
Alternatively, the defective germination process of C. albicans
TPK1 mutants (40) could also explain the reduced effect of
MAb C7 on these strains, as this MAb mainly reacts with the
surface components of the germ tubes (29).
Iron limitation may have multiple effects on fungal cells,
including the loss of activity of iron-dependent enzymes and a
depletion of cell energy (28). Since MAb C7 binds to cell wall
components of C. albicans, including Als3 and enolase (4, 26,
29), it is likely that interaction of MAb C7 with cell wall
proteins involved in the reductive pathway for iron acquisition
causes the blockage of the pathway and explains the candi-
dacidal activity of the MAb. Interestingly, it has recently been
reported that Als3 mediates iron acquisition from host ferritin
by binding the iron storage protein to C. albicans (1). In our
study, none of the TR-CaENO1/Caeno1 or als3/als3 mu-
tants were resistant to the candidacidal effect of MAb C7.
These results were possibly related to the existence of a com-
pensatory effect, since as MAb C7 recognizes both enolase and
Als3, in the absence of one of these proteins, MAb C7 could
still react with the other.
Ibrahim et al. (13) evaluated the iron chelator deferasirox as
a therapeutic adjuvant for mucormycosis, and they concluded
that abrogation of iron acquisition by the agents of mucormy-
cosis was a promising therapeutic strategy to improve clinical
outcomes (13, 34). Thus far, MAb C7 has shown a protective
effect in a murine model of invasive candidiasis (37). In a way
similar to that put forward for deferasirox, if the candidacidal
effect of MAb C7 is related to the blockage of iron uptake by
the reductive pathway of C. albicans, we could expect a poten-
tial therapeutic application of the MAb, in combination with
current antifungals.
In conclusion, our data suggest that the candidacidal activity
of MAb C7 is related to a blockage of the reductive iron
acquisition pathway of C. albicans that induces changes in the
iron metabolism resembling those found under iron-limiting
conditions. Further work to elucidate the therapeutic potential
of MAb C7 is warranted.
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